RNA Formulation Resources
-
An Introduction And Brief History Of mRNA-LNPs
12/14/2023
With adjustable components and increased stability during bloodstream circulation, LNPs are significantly advancing drug development and delivery, particularly for mRNA vaccines.
-
Transfection Solutions For Highly Reliable And Effective Gene Silencing With siRNA And Co.
2/4/2022
We discuss the process of transfection and highlight two highly effective vectors for both in vitro and in vivo gene therapy applications.
-
PEG In LNP Formulations: Addressing Challenges And Seeking Solutions
2/8/2024
Polyethylene glycol and similar variants have driven innovative research for therapies. However, the continued use of PEG poses significant drawbacks.
-
Redefining Biomanufacturing For Personalized Cancer Vaccines
4/24/2026
Personalized cancer vaccines need fast, flexible manufacturing. Cell‑free synthetic DNA enables rapid, small‑batch mRNA production, supporting individualized therapies beyond plasmid‑based limits.
-
Why Risk Analysis And Lane Qualification Matter
5/28/2026
Risk analysis and lane qualification show supply chains perform consistently, meeting regulatory expectations by demonstrating control, reducing variability, and ensuring reliable delivery.
-
Advancing RNA-LNP Therapeutics As An Alternative To Viral Vectors
11/17/2025
RNA-LNP therapeutics offer a flexible, transient alternative to traditional viral vectors for genetic medicine. Learn about the advantages of LNPs in safety, scalability, and payload versatility.
-
The Key To Accelerating RNA-LNP Drug Development
12/27/2023
Learn about the drug development hurdles that must be overcome to deliver on the promise of mRNA.
-
Advancing Cell Therapies With Lipid Nanoparticles
3/24/2025
Cell therapies, using reprogrammed immune cells, offer innovative treatments for diseases. Discover how lipid nanoparticles (LNPs) enhance these therapies by delivering RNA for gene modulation and next-gen treatments.
-
Optimizing GMP Manufacturing Of Lipid Nanoparticles For mRNA Encapsulation
10/9/2026
Moving mRNA lipid nanoparticle encapsulation from pre-clinical work to cGMP production is often underestimated. Early process parameter definition, raw material control, and scalable mixing determine how low-risk that transition becomes.
-
Drug Discovery And Screening, A Digital Era For RNA-LNP Therapeutics
11/21/2022
Learn about the key stages of drug discovery and screening as well as how to overcome bottlenecks in screening mRNA-LNPs to rapidly develop genomic medicines.